Biology:Savolitinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Volitinib |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C17H15N9 |
| Molar mass | 345.370 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2] It has been given conditional approval for these indication in China.[3]
References
- ↑ "Savolitinib". Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016. https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fsavolitinib.pdf.
- ↑ "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800035893.
- ↑ "Savolitinib: First Approval". Drugs 81 (14): 1665–1670. September 2021. doi:10.1007/s40265-021-01584-0. PMID 34455538.
External links
- "Savolitinib". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/savolitinib.
| Products | |
|---|---|
| Predecessors and acquired companies | |
| People | |
 |  |
